Biomarker discovery platform
An efficient and versatile platform.
ALCEDIAG proposes a service of biomarkers discovery based on the company experience and expertise on RNA editing.
This platform can be used whenever the pathology targeted is related to RNA editing modifications. Such relations have been identified so far for a large number of diseases including:
- Neuropsychiatric diseases: depression, bipolar disorders, schizophrenia, Alzheimer’s, suicidal behavior, etc.;
- Inflammatory diseases: Systemic Lupus Erythematosus, Aicardi Gouttiere syndrom, systemic inflammation, etc.
- Cancer: hepatocellular carcinoma, breast, lung, kidney, prostate cancer, metastatic melanoma, etc.
During a rapid process that lasts no more than a few months, ALCEDIAG performs a series of blood NGS analyses on a set of patients and controls, as well as network analysis. The company can then confirm the results on a discovery cohort. ALCEDIAG adapts the process to its clients’ needs, to the pathology and to the clinical question addressed.